SG10201406063XA - Drug fusions and conjugates with extended half life - Google Patents
Drug fusions and conjugates with extended half lifeInfo
- Publication number
- SG10201406063XA SG10201406063XA SG10201406063XA SG10201406063XA SG10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugates
- half life
- extended half
- drug fusions
- fusions
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24734609P | 2009-09-30 | 2009-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201406063XA true SG10201406063XA (en) | 2014-11-27 |
Family
ID=43130084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201406063XA SG10201406063XA (en) | 2009-09-30 | 2010-09-23 | Drug fusions and conjugates with extended half life |
Country Status (13)
Country | Link |
---|---|
US (2) | US20120276098A1 (de) |
EP (1) | EP2483308A1 (de) |
JP (1) | JP2013506628A (de) |
KR (1) | KR20120092611A (de) |
CN (2) | CN102666586A (de) |
AU (1) | AU2010303112A1 (de) |
BR (1) | BR112012007374A2 (de) |
CA (1) | CA2774552A1 (de) |
EA (1) | EA201290123A1 (de) |
IL (1) | IL218651A0 (de) |
MX (1) | MX2012003939A (de) |
SG (1) | SG10201406063XA (de) |
WO (1) | WO2011039096A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR075505A1 (es) * | 2009-02-19 | 2011-04-06 | Glaxo Group Ltd | Variantes de union a anti- albumina de suero mejoradas |
TW201100104A (en) * | 2009-03-27 | 2011-01-01 | Glaxo Group Ltd | Drug fusions and conjugates |
ES2637952T3 (es) * | 2010-04-27 | 2017-10-18 | Chr. Hansen A/S | Método para la preparación de una bebida fermentada |
EP2571900A1 (de) * | 2010-05-20 | 2013-03-27 | Glaxo Group Limited | Verbesserte antiserumalbuminbindende varianten |
EP2603522A1 (de) * | 2010-08-13 | 2013-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Verbesserte antiserumalbuminbindende varianten |
CN102718868A (zh) * | 2011-03-30 | 2012-10-10 | 上海华谊生物技术有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
WO2012136792A2 (en) * | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Cck compositions |
EP2729481B1 (de) * | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Manipulierte polypeptide mit verbesserter wirkungsdauer und reduzierter immunogenität |
CN102382191A (zh) * | 2011-09-23 | 2012-03-21 | 江南大学 | 一种新型脑肠肽激动剂分子的制备方法及其应用 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
US20150368292A1 (en) * | 2013-01-31 | 2015-12-24 | Glaxo Group Limited | Method of producing a protein |
AU2014261111B2 (en) | 2013-05-02 | 2017-03-16 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
WO2015030539A1 (en) * | 2013-08-30 | 2015-03-05 | Aprilbio Co., Ltd | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof |
JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080154B1 (de) | 2013-12-13 | 2018-02-07 | Sanofi | Duale glp-1/gip-rezeptoragonisten |
EP4212180A1 (de) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modifizierte therapeutika, geklammerte peptidlipidkonjugate und zusammensetzungen davon |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
AU2015269210A1 (en) * | 2014-06-06 | 2016-12-08 | The California Institute For Biomedical Research | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CN106397606B (zh) * | 2015-01-28 | 2020-11-10 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物 |
JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー/エス | 極性の組換え延長部を有するインスリン |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
CN110049997B (zh) | 2016-12-07 | 2023-09-22 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
CN110582302A (zh) * | 2016-12-14 | 2019-12-17 | 利甘达尔股份有限公司 | 用于核酸和/或蛋白有效负载递送的组合物和方法 |
JP7300385B2 (ja) | 2017-01-17 | 2023-06-29 | アブリンクス エン.ヴェー. | 改善された血清アルブミン結合剤 |
CN117285623A (zh) | 2017-01-17 | 2023-12-26 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
JP7332157B2 (ja) | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
EP3606560A2 (de) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomererweiterte insulin-fc-konjugate |
JP7095078B2 (ja) | 2017-09-22 | 2022-07-04 | カイト ファーマ インコーポレイテッド | キメラポリペプチド及びその使用 |
CN108426995A (zh) * | 2018-02-26 | 2018-08-21 | 徐州医科大学 | 一种基于药物靶点停留时间的细胞洗脱方法 |
US10875902B2 (en) | 2018-04-25 | 2020-12-29 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
TW202014433A (zh) * | 2018-04-25 | 2020-04-16 | 比利時商健生藥品公司 | 類升糖素肽1(glp-1)融合肽偶合環狀酪酪肽接合物及其用途 |
US11753455B2 (en) | 2018-06-21 | 2023-09-12 | Novo Nordisk A/S | Compounds for treatment of obesity |
CN111234015B (zh) * | 2020-02-12 | 2021-04-06 | 康维众和(中山)生物药业有限公司 | 用于延长药物半衰期的抗体、其融合蛋白和应用 |
WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0546073B1 (de) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
AU4063697A (en) | 1996-08-08 | 1998-02-25 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
DE69826697T2 (de) | 1997-07-07 | 2006-02-16 | Medical Research Council | In vitro selektionsmethode |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
ATE381939T1 (de) | 1997-11-14 | 2008-01-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
AU756836B2 (en) | 1997-11-14 | 2003-01-23 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
EP1056775B1 (de) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
CZ308214B6 (cs) | 2000-12-07 | 2020-03-04 | Eli Lilly And Company | GLP-1 fúzní proteiny |
EP1412384B1 (de) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2261250B1 (de) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin Fusionsproteine |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
WO2005118642A2 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
KR20070094909A (ko) * | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
TW200938222A (en) * | 2007-12-13 | 2009-09-16 | Glaxo Group Ltd | Compositions for pulmonary delivery |
SG189682A1 (en) * | 2008-03-31 | 2013-05-31 | Glaxo Group Ltd | Drug fusions and conjugates |
MA33052B1 (fr) * | 2009-02-19 | 2012-02-01 | Glaxo Group Ltd | Variants de liaison anti-albumine sérique améliorés |
AR075505A1 (es) * | 2009-02-19 | 2011-04-06 | Glaxo Group Ltd | Variantes de union a anti- albumina de suero mejoradas |
TW201100104A (en) * | 2009-03-27 | 2011-01-01 | Glaxo Group Ltd | Drug fusions and conjugates |
-
2010
- 2010-09-23 US US13/498,924 patent/US20120276098A1/en not_active Abandoned
- 2010-09-23 BR BR112012007374A patent/BR112012007374A2/pt not_active IP Right Cessation
- 2010-09-23 AU AU2010303112A patent/AU2010303112A1/en not_active Abandoned
- 2010-09-23 EP EP10762634A patent/EP2483308A1/de not_active Withdrawn
- 2010-09-23 JP JP2012531329A patent/JP2013506628A/ja active Pending
- 2010-09-23 KR KR1020127011105A patent/KR20120092611A/ko not_active Application Discontinuation
- 2010-09-23 CN CN2010800538921A patent/CN102666586A/zh active Pending
- 2010-09-23 CA CA2774552A patent/CA2774552A1/en not_active Abandoned
- 2010-09-23 SG SG10201406063XA patent/SG10201406063XA/en unknown
- 2010-09-23 MX MX2012003939A patent/MX2012003939A/es not_active Application Discontinuation
- 2010-09-23 CN CN201410386267.9A patent/CN104147611A/zh active Pending
- 2010-09-23 WO PCT/EP2010/064020 patent/WO2011039096A1/en active Application Filing
- 2010-09-23 EA EA201290123A patent/EA201290123A1/ru unknown
-
2012
- 2012-03-15 IL IL218651A patent/IL218651A0/en unknown
-
2013
- 2013-11-18 US US14/082,888 patent/US20140227264A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011039096A1 (en) | 2011-04-07 |
CN102666586A (zh) | 2012-09-12 |
EP2483308A1 (de) | 2012-08-08 |
MX2012003939A (es) | 2012-07-30 |
US20120276098A1 (en) | 2012-11-01 |
US20140227264A1 (en) | 2014-08-14 |
AU2010303112A1 (en) | 2012-04-26 |
CN104147611A (zh) | 2014-11-19 |
BR112012007374A2 (pt) | 2019-09-24 |
KR20120092611A (ko) | 2012-08-21 |
EA201290123A1 (ru) | 2012-10-30 |
CA2774552A1 (en) | 2011-04-07 |
IL218651A0 (en) | 2012-05-31 |
JP2013506628A (ja) | 2013-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL218651A0 (en) | Drug fusions and conjugates with extended half life | |
ZA201107022B (en) | Drug fusions and conjugates | |
HRP20181493T1 (hr) | Konjugati epsilon-polilizin i njihova primjena | |
ZA201006763B (en) | Drug fusions and conjugates | |
ZA201204480B (en) | Conjugate with target-finding ligand and use thereof | |
SG2014012918A (en) | Albumin variants and conjugates | |
EP2486918A4 (de) | Pharmazeutische zusammensetzung mit sowohl sofortiger als auch verzögerter freisetzung | |
ZA201308703B (en) | Novel maytansinoid derivatives with peptide linker and conjugates thereof | |
ZA201105623B (en) | Aminopyrazine derivative and medicine | |
IL213848A0 (en) | Fgf21 derivatives with albumin binder a-b-c-d-e-and their use | |
ZA201109034B (en) | Aminopyrrolidinone derivatives and uses thereof | |
IL213974A0 (en) | Isoxazole-isoxazole and isoxazole-isothiazole derivatives | |
EP2575887A4 (de) | Optimierte arzneimittelkonjugate | |
EP2391217A4 (de) | Synthetische konjugate und ihre verwendung | |
HK1178526A1 (en) | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7- | |
GB0906195D0 (en) | Needle and syringe | |
IL219768A0 (en) | Drug combination with thebromine and its use in therapy | |
IL219769A0 (en) | Drug combination with theromine and its use in therapy | |
EP2440055A4 (de) | Styryltriazinderivate und deren therapeutische anwendungen | |
ZA201202203B (en) | Drug fusions and conjugates with extended half life | |
ZA201108276B (en) | Redox drug derivatives | |
EP2408808A4 (de) | Terminal-funktionalisierte konjugate und ihre verwendung | |
HK1218538A1 (zh) | 哌嗪衍生物及其藥物用途 | |
TWM371940U (en) | Exhibiting body with advertisement feature | |
GB0908338D0 (en) | Redox drug derivatives |